

4DMedical wins contract with University of Chicago Medicine

16 December 2024

Highlights

- 4DMedical enters a commercial contract with the University of Chicago Medicine, a nationally recognised academic medical center
- The agreement allows University of Chicago Medicine clinicians to utilise 4DMedical's comprehensive portfolio of structural and functional lung imaging products, including CT LVAS™
- 4DMedical also expands recent University of California San Diego (UCSD) Health contract

Melbourne, Australia, 16 December 2024: 4DMedical Limited (ASX: 4DX) ("4DMedical" or the "Company"), a leading innovator in respiratory imaging technology, today announces a new partnership with nationally recognised University of Chicago Medicine (UChicago Medicine). The agreement allows UChicago Medicine clinicians to utilise 4DMedical's comprehensive portfolio of structural and functional lung imaging products, including CT LVAS™. The Company also announces the expansion of the recently signed UCSD Health contract.

University of Chicago Medicine

UChicago Medicine is an academic medical center (AMC) whose Pulmonary and Critical Care Medicine Department is internationally recognised for its contributions to advancing the treatment of complex lung diseases. As with other AMCs, many of UChicago Medicine's doctors split their time conducting cutting-edge research as well as treating patients. The integration of 4DMedical's revolutionary imaging technology will enable UChicago Medicine to deliver unparalleled precision in the diagnosis and management of lung conditions, further enhancing its role as a leader in pulmonary care innovation.

Dr. Kyle Hogarth expresses his enthusiasm for this partnership

Dr. Kyle Hogarth, an internationally acclaimed Pulmonologist, Professor of Medicine, Director of Bronchoscopy at UChicago Medicine, and a long-time advocate of innovative imaging approaches to enhance patient outcomes, expressed his enthusiasm for this partnership: "Our medical center has seen firsthand the benefits of 4DMedical's technology and the many clinical programs it has helped. We have always wanted to maximize the CT scan for the sake of our patients - to make the most of the radiation we have used. With the addition of CT LVAS™ and other products we believe we have taken the next step in maximizing the information that can be obtained from a chest CT. I am glad the University of Chicago is leading the way in utilizing this amazing technology so that we can provide the best care to our patients."

By signing this contract with UChicago Medicine, 4DMedical is accelerating the roll-out of its technology at important AMCs, and with key opinion leaders, establishing reference sites across the United States. These partnerships highlight the value of 4DMedical's comprehensive suite of imaging solutions that enhance clinical decision-making. The contract value is commercial-in-confidence, extending for a 12-month renewable term, reflecting the ongoing traction and strategic alignment of 4DMedical's solutions within the U.S. healthcare ecosystem.



4DMedical expands recent UCSD Health contract

The agreement with UChicago Medicine builds on 4DMedical's recent commercial momentum, including the announcement of its contract with UCSD Health. UCSD has now expanded this agreement to include SeleCT, a screening service that analyses chest CTs to identify patients for suitable for treatment with endobronchial valves.

Radiologist and Division Chief of cardiothoracic imaging at UCSD Health, Dr Jonathon Chung, specialises in chronic and diffuse lung diseases. Dr. Chung is an expert in interstitial lung disease, occupational lung disease, nontuberculous mycobacterial pneumonia, and large and small airway diseases. Dr Chung said, "The 4D Medical algorithms are obviously valuable for diagnosis of disease and quantification of extent, especially in the setting of longitudinal follow up of chronic lung diseases. However, from a broader standpoint, they are extremely valuable for population screening of imaging studies. The vast majority of the data that we acquire in the setting of medical imaging is 'thrown away' because it does not directly address the clinical question at hand. However, given our aging population, every imaging encounter is a valuable opportunity to screen patients for chronic cardiothoracic diseases such as emphysema, small airways disease, pulmonary fibrosis, and coronary artery disease. The automated algorithms, combined with the agile IT expertise of the 4DMedical team, allow radiologists to easily leverage this data without manual lifting. This will not only improve population healthcare at a medical center but also can help with the bottom line for the hospital as patients are directed into the correct sub specialized clinics for appropriate therapy and procedures, which is increasingly important in the current healthcare environment."

4DMedical MD/CEO and Founder Andreas Fouras said:

Our win with UChicago Medicine signifies another critical step in our U.S. expansion strategy and underscores the rapidly growing recognition of 4DMedical's innovative technology in transforming respiratory care. The combination of functional lung imaging derived from CT LVAS™ and quantitative structural information, sets the standard for pulmonary imaging. This contract, in combination with the immediate growth in contract value from UCSD Health, clearly demonstrates the demand for our comprehensive portfolio of products. Management is excited by our sales pipeline, and I look forward to keeping the market up to date on our progress.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[®], 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[®]) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS[™].

XV LVAS[®] and CT LVAS[™] reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4Dmedical.com

For personal use only